Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015: mortality of non-endometrioid cancer on the rise?

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Standard

Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015 : mortality of non-endometrioid cancer on the rise? / Gustafson, Line Winther; Booth, Berit Bargum; Kahlert, Johnny; Ørtoft, Gitte; Mejlgaard, Else; Clarke, Megan; Wentzensen, Nicolas ; Rositch, Anne; Hammer, Anne.

I: International Journal of Cancer, Bind 148, Nr. 3, 02.2021.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Gustafson, Line Winther ; Booth, Berit Bargum ; Kahlert, Johnny ; Ørtoft, Gitte ; Mejlgaard, Else ; Clarke, Megan ; Wentzensen, Nicolas ; Rositch, Anne ; Hammer, Anne. / Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015 : mortality of non-endometrioid cancer on the rise?. I: International Journal of Cancer. 2021 ; Bind 148, Nr. 3.

Bibtex

@article{03e735adc34745da99dc4afe279e2bcf,
title = "Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015: mortality of non-endometrioid cancer on the rise?",
abstract = "Corpus uteri cancer is the most common gynecological malignancy in most developed countries. The disease is typically diagnosed at an early stage, is of endometrioid histologic subtype, and has a fairly good prognosis. Here, we describe hysterectomy-corrected mortality rates of corpus uteri cancer, overall and stratified by age, stage and histologic subtype. Using data from nationwide Danish registries, we calculated uncorrected and hysterectomy-corrected age-standardized mortality rates of corpus uteri cancer among women ≥35 years during 2002 to 2015. Individual-level hysterectomy status was obtained from national registries; hysterectomy-corrected mortality rates were calculated by subtracting posthysterectomy person-years from the denominator, unless hysterectomy was performed due to corpus uteri cancer. Correction for hysterectomy resulted in a 25.5% higher mortality rate (12.3/100000 person-years vs 9.8/100000 person-years). Mortality rates were highest in women aged 70+, irrespective of year of death, histologic subtype and stage. A significant decline was observed in overall hysterectomy-corrected mortality rates from 2002 to 2015, particularly among women aged 70+. Mortality rates of endometrioid cancer declined significantly over time (annual percent change [APC]: −2.32, 95% CI −3.9, −0.7, P =.01), whereas rates of nonendometrioid cancer increased (APC: 5.90, 95% CI: 3.0, 8.9, P <.001). With respect to stage, mortality rates increased significantly over time for FIGOI-IIa (APC: 6.18 [95% CI: 1.9, 10.7] P =.01) but remained unchanged for FIGO IIb-IV. In conclusion, increasing mortality rates of nonendometrioid cancer paralleled the previously observed rise in incidence rates of this histologic subtype. Given the poor prognosis of nonendometrioid cancer, more studies are needed to clarify the underlying reason for these findings.",
keywords = "hysterectomy, mortality, survival rate, uterine cancer",
author = "Gustafson, {Line Winther} and Booth, {Berit Bargum} and Johnny Kahlert and Gitte {\O}rtoft and Else Mejlgaard and Megan Clarke and Nicolas Wentzensen and Anne Rositch and Anne Hammer",
year = "2021",
month = feb,
doi = "10.1002/ijc.33219",
language = "English",
volume = "148",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "JohnWiley & Sons, Inc.",
number = "3",

}

RIS

TY - JOUR

T1 - Trends in hysterectomy-corrected uterine cancer mortality rates during 2002-2015

T2 - mortality of non-endometrioid cancer on the rise?

AU - Gustafson, Line Winther

AU - Booth, Berit Bargum

AU - Kahlert, Johnny

AU - Ørtoft, Gitte

AU - Mejlgaard, Else

AU - Clarke, Megan

AU - Wentzensen, Nicolas

AU - Rositch, Anne

AU - Hammer, Anne

PY - 2021/2

Y1 - 2021/2

N2 - Corpus uteri cancer is the most common gynecological malignancy in most developed countries. The disease is typically diagnosed at an early stage, is of endometrioid histologic subtype, and has a fairly good prognosis. Here, we describe hysterectomy-corrected mortality rates of corpus uteri cancer, overall and stratified by age, stage and histologic subtype. Using data from nationwide Danish registries, we calculated uncorrected and hysterectomy-corrected age-standardized mortality rates of corpus uteri cancer among women ≥35 years during 2002 to 2015. Individual-level hysterectomy status was obtained from national registries; hysterectomy-corrected mortality rates were calculated by subtracting posthysterectomy person-years from the denominator, unless hysterectomy was performed due to corpus uteri cancer. Correction for hysterectomy resulted in a 25.5% higher mortality rate (12.3/100000 person-years vs 9.8/100000 person-years). Mortality rates were highest in women aged 70+, irrespective of year of death, histologic subtype and stage. A significant decline was observed in overall hysterectomy-corrected mortality rates from 2002 to 2015, particularly among women aged 70+. Mortality rates of endometrioid cancer declined significantly over time (annual percent change [APC]: −2.32, 95% CI −3.9, −0.7, P =.01), whereas rates of nonendometrioid cancer increased (APC: 5.90, 95% CI: 3.0, 8.9, P <.001). With respect to stage, mortality rates increased significantly over time for FIGOI-IIa (APC: 6.18 [95% CI: 1.9, 10.7] P =.01) but remained unchanged for FIGO IIb-IV. In conclusion, increasing mortality rates of nonendometrioid cancer paralleled the previously observed rise in incidence rates of this histologic subtype. Given the poor prognosis of nonendometrioid cancer, more studies are needed to clarify the underlying reason for these findings.

AB - Corpus uteri cancer is the most common gynecological malignancy in most developed countries. The disease is typically diagnosed at an early stage, is of endometrioid histologic subtype, and has a fairly good prognosis. Here, we describe hysterectomy-corrected mortality rates of corpus uteri cancer, overall and stratified by age, stage and histologic subtype. Using data from nationwide Danish registries, we calculated uncorrected and hysterectomy-corrected age-standardized mortality rates of corpus uteri cancer among women ≥35 years during 2002 to 2015. Individual-level hysterectomy status was obtained from national registries; hysterectomy-corrected mortality rates were calculated by subtracting posthysterectomy person-years from the denominator, unless hysterectomy was performed due to corpus uteri cancer. Correction for hysterectomy resulted in a 25.5% higher mortality rate (12.3/100000 person-years vs 9.8/100000 person-years). Mortality rates were highest in women aged 70+, irrespective of year of death, histologic subtype and stage. A significant decline was observed in overall hysterectomy-corrected mortality rates from 2002 to 2015, particularly among women aged 70+. Mortality rates of endometrioid cancer declined significantly over time (annual percent change [APC]: −2.32, 95% CI −3.9, −0.7, P =.01), whereas rates of nonendometrioid cancer increased (APC: 5.90, 95% CI: 3.0, 8.9, P <.001). With respect to stage, mortality rates increased significantly over time for FIGOI-IIa (APC: 6.18 [95% CI: 1.9, 10.7] P =.01) but remained unchanged for FIGO IIb-IV. In conclusion, increasing mortality rates of nonendometrioid cancer paralleled the previously observed rise in incidence rates of this histologic subtype. Given the poor prognosis of nonendometrioid cancer, more studies are needed to clarify the underlying reason for these findings.

KW - hysterectomy

KW - mortality

KW - survival rate

KW - uterine cancer

UR - http://www.scopus.com/inward/record.url?scp=85089554423&partnerID=8YFLogxK

U2 - 10.1002/ijc.33219

DO - 10.1002/ijc.33219

M3 - Journal article

C2 - 32683690

VL - 148

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 3

ER -